Evidence map›Paper›PMID 38410681›Full record

ArticleMultiple sclerosis journal - experimental, translational and clinical

Frequency of cognitive impairment in patients with neuromyelitis optica spectrum disorder in Mexico.

Edgar R Valdivia-Tangarife, Fernando Cortés-Enríquez, Alejandra Morlett-Paredes, Teresita Villaseñor-Cabrera, Jorge I Gámez-Nava, Mario A Mireles-Ramírez, Laura González-López, Miguel Á Macías-Islas

Abstract read
In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Edgar R Valdivia-TangarifeDepartamento de Neurociecias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México.
Fernando Cortés-EnríquezDepartamento de Neurología, Hospital General, No 14 del Instituto Mexicano del Seguro Social, Guadalajara, México.
Alejandra Morlett-ParedesDepartamento de Neurociencias, Universidad de California San Diego, La Jolla, CA, USA.
Teresita Villaseñor-CabreraDepartamento de Neurociecias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México.
Jorge I Gámez-NavaPrograma de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México.
Mario A Mireles-RamírezDepartamento de Neurología, Unidad de Alta Especialidad Médica, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, México.
Laura González-LópezPrograma de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México.
Miguel Á Macías-IslasDepartamento de Neurociecias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, México.ORCID https://orcid.org/0000-0002-0936-7525

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Between 29% and 67% of neuromyelitis optica spectrum disorder patients have cognitive alterations. Objective: To assess the frequency of cognitive impairment in patients with neuromyelitis optica spectrum disorder in Mexico using the Brief International Cognitive Assessment for Multiple Sclerosis. Methods: We evaluated 40 neuromyelitis optica spectrum disorder patients and 40 healthy controls from Mexico. Results: 28 (70.0%) patients with neuromyelitis optica spectrum disorder had cognitive impairment in two or more cognitive domains. Student´s T test showed statistically poor performance by neuromyelitis optica spectrum disorder patients compared to healthy controls on all three neuropsychological test scores. This significant difference was observed on the Symbols Digit Modalities Test ( Conclusions: This study showed that 70% of neuromyelitis optica spectrum disorder patients exhibited cognitive impairment in two or more cognitive domains. Determining the frequency of cognitive impairment will guide the decision of Neuropsychologists in planning cognitive rehabilitation across various domains.

Indexed as

Brief International Cognitive Assessment for Multiple SclerosisCognitive impairmentneuromyelitis optica spectrum disordersprocessing speedverbal memoryvisuospatial memory

Identifiers

PMID38410681
PMCPMC10896058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.